Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Cancer Therapeutics Market: By Top Selling Drugs: Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Others; By Application; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Cancer Therapeutics Market Outlook
The global cancer therapeutics market stood at a value of USD 109,268.7 million in 2020 and is expected to achieve USD 194,634.5 million by 2026, recording a CAGR of 10.1% between 2021 and 2026.
The cancer therapeutics market is being driven by the increased investment by companies in the R&D sector. The increasing incidences of cancer across the globe are also adding to the cancer therapeutics market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Cancer therapy includes the use and administration of chemotherapy and oncology drugs for the treatment of cancer. It is a type of treatment that identifies and attacks particular kinds of cancer cells with less damage to ordinary cells with the help of drugs or other substances. Some targeted therapies block certain enzymes, proteins, or other molecules that are engaged in cancer cell development.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The cancer therapeutics market can be divided on the basis of segments like application and top-selling drugs. The industry can be broadly categorised based on its application into:
- Blood cancer
- Lung cancer
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Head and neck cancer
- Glioblastoma
- Malignant Meningioma
- Mesothelioma
- Melanoma
- Others
The cancer therapeutics market can be divided on the basis of its top-selling drugs as Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others.
The EMR report looks into the regional cancer therapeutics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
An increase in the incidences of cancer, rising cooperation among pharmaceutical companies, and growing innovation in the cancer-research sector are factors that are driving the growth of the cancer therapeutics industry. It is anticipated that the geriatric population will increase over the forecast period, further increasing the demand for cancer therapy. Further, the rising demand for personalised medicine and increased investment in the healthcare sector, particularly in developing countries, is providing the cancer therapeutics market with new growth opportunities. Some of the factors that restrict cancer therapeutics market growth are high costs connected with oncology drug development and adverse effects associated with cancer therapy.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global cancer therapeutics market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- AbbVie Inc. (NYSE: ABBV)
- Astellas Pharma Inc.
- Bristol Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Top Selling Drugs, Application, Region |
| Breakup by Top Selling Drugs | Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, Others |
| Breakup by Application | Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Head & Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | AbbVie Inc. [ABBV (NYSE)], Astellas Pharma Inc. [4503 (TYO)], Bristol Myers Squibb Company [BMY (NYSE)], Celgene Corporation [CELG (NASDAQ)], F. Hoffmann-La Roche Ltd. [ROG (SWX)], Johnson & Johnson [JNJ (NYSE)], Merck & Co., Inc. [MRK (NYSE)], Novartis AG [NOVN (SWX)], Pfizer Inc. [PFE (NYSE)], Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cancer Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Cancer Therapeutics Historical Market (2018-2022)
8.3 Global Cancer Therapeutics Market Forecast (2023-2028)
8.4 Global Cancer Therapeutics Market by Top Selling Drugs
8.4.1 Revlimid
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Avastin
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Herceptin
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Rituxan
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.4.5 Opdivo
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2018-2022)
8.4.5.3 Forecast Trend (2023-2028)
8.4.6 Gleevec
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2018-2022)
8.4.6.3 Forecast Trend (2023-2028)
8.4.7 Velcade
8.4.7.1 Market Share
8.4.7.2 Historical Trend (2018-2022)
8.4.7.3 Forecast Trend (2023-2028)
8.4.8 Imbruvica
8.4.8.1 Market Share
8.4.8.2 Historical Trend (2018-2022)
8.4.8.3 Forecast Trend (2023-2028)
8.4.9 Ibrance
8.4.9.1 Market Share
8.4.9.2 Historical Trend (2018-2022)
8.4.9.3 Forecast Trend (2023-2028)
8.4.10 Zytiga
8.4.10.1 Market Share
8.4.10.2 Historical Trend (2018-2022)
8.4.10.3 Forecast Trend (2023-2028)
8.4.11 Alimta
8.4.11.1 Market Share
8.4.11.2 Historical Trend (2018-2022)
8.4.11.3 Forecast Trend (2023-2028)
8.4.12 Xtandi
8.4.12.1 Market Share
8.4.12.2 Historical Trend (2018-2022)
8.4.12.3 Forecast Trend (2023-2028)
8.4.13 Tarceva
8.4.13.1 Market Share
8.4.13.2 Historical Trend (2018-2022)
8.4.13.3 Forecast Trend (2023-2028)
8.4.14 Perjeta
8.4.14.1 Market Share
8.4.14.2 Historical Trend (2018-2022)
8.4.14.3 Forecast Trend (2023-2028)
8.4.15 Temodar
8.4.15.1 Market Share
8.4.15.2 Historical Trend (2018-2022)
8.4.15.3 Forecast Trend (2023-2028)
8.4.16 Others
8.5 Global Cancer Therapeutics Market by Application
8.5.1 Blood Cancer
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Lung Cancer
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Breast Cancer
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Colorectal Cancer
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Prostate Cancer
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2018-2022)
8.5.5.3 Forecast Trend (2023-2028)
8.5.6 Cervical Cancer
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2018-2022)
8.5.6.3 Forecast Trend (2023-2028)
8.5.7 Head and Neck Cancer
8.5.7.1 Market Share
8.5.7.2 Historical Trend (2018-2022)
8.5.7.3 Forecast Trend (2023-2028)
8.5.8 Glioblastoma
8.5.8.1 Market Share
8.5.8.2 Historical Trend (2018-2022)
8.5.8.3 Forecast Trend (2023-2028)
8.5.9 Malignant Meningioma
8.5.9.1 Market Share
8.5.9.2 Historical Trend (2018-2022)
8.5.9.3 Forecast Trend (2023-2028)
8.5.10 Mesothelioma
8.5.10.1 Market Share
8.5.10.2 Historical Trend (2018-2022)
8.5.10.3 Forecast Trend (2023-2028)
8.5.11 Melanoma
8.5.11.1 Market Share
8.5.11.2 Historical Trend (2018-2022)
8.5.11.3 Forecast Trend (2023-2028)
8.5.12 Others
8.6 Global Cancer Therapeutics Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 AbbVie Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Astellas Pharma Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Bristol-Myers Squibb Company
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Celgene Corporation
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 F. Hoffmann-La Roche Ltd
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Johnson & Johnson
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Merck & Co., Inc.
12.2.7.1 Company Overview
12.2.7.2 Product Portfolio
12.2.7.3 Demographic Reach and Achievements
12.2.7.4 Certifications
12.2.8 Novartis AG
12.2.8.1 Company Overview
12.2.8.2 Product Portfolio
12.2.8.3 Demographic Reach and Achievements
12.2.8.4 Certifications
12.2.9 Pfizer Inc.
12.2.9.1 Company Overview
12.2.9.2 Product Portfolio
12.2.9.3 Demographic Reach and Achievements
12.2.9.4 Certifications
12.2.10 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Cancer Therapeutics Market: Key Industry Highlights, 2018 and 2028
2. Global Cancer Therapeutics Historical Market: Breakup by Top Selling Drugs (USD Million), 2018-2022
3. Global Cancer Therapeutics Market Forecast: Breakup by Top Selling Drugs (USD Million), 2023-2028
4. Global Cancer Therapeutics Historical Market: Breakup by Application (USD Million), 2018-2022
5. Global Cancer Therapeutics Market Forecast: Breakup by Application (USD Million), 2023-2028
6. Global Cancer Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2022
7. Global Cancer Therapeutics Market Forecast: Breakup by Region (USD Million), 2023-2028
8. North America Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
9. North America Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Europe Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
11. Europe Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Asia Pacific Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
13. Asia Pacific Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Latin America Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
15. Latin America Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Middle East and Africa Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
17. Middle East and Africa Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Global Cancer Therapeutics Market Structure
Key Questions Answered in the Report
In 2020, the global cancer therapeutics market attained a value of nearly USD 109,268.7 million.
The market is projected to grow at a CAGR of 10.1% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2021-2026 to reach USD 194,634.5 million by 2026.
The major drivers of the market include the increase in research and development activities, rising cooperation among pharmaceutical companies, rising geriatric population, rising demand for personalised medicine, and increased investment in the healthcare sector.
Increasing incidences of cancer, and growing innovation in the cancer-research sector are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The cancer therapeutics market can be divided on the basis of its top-selling drugs into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others.
Cancer therapeutics find their major application in sectors like blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, and melanoma, among others.
The major players in the industry are AbbVie Inc. , Astellas Pharma Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others.
Analyst Review
The global cancer therapeutics market attained a value of nearly USD 109,268.7 million in 2020, driven by the increasing incidences of cancer. Aided by increased investment in the healthcare sector and growing innovation in the cancer-research sector, the market is expected to witness further growth in the forecast period of 2021-2026, growing at a CAGR of 10.1% to reach USD 194,634.5 million by 2026.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The cancer therapeutics market can be divided on the basis of its top-selling drugs into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others. Cancer therapeutics find their major application in sectors like blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, and melanoma, among others. The major regional markets for the cancer therapeutics market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The major players in the industry are AbbVie Inc. , Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER